Skip to main content

EQT Life Sciences — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

81
Companies
$5.2B
Total invested
$64.6M
Avg. check
15
Industries
Biotechnology 16Health Care 15Medical 10Pharmaceutical 8Medical Device 8Therapeutics 8+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 81
AstronauTx
September 2026

AstronauTx is a biotechnology company that develops small-molecule therapeutics for neurological diseases by targeting sleep architecture.

Biotechnology · London$1.2M Grant
Neurent Medical
September 2026

Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases.

Health Care · Oranmore$29.1M Debt Financing
Vaderis Therapeutics
August 2026

Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases.

Biotechnology · Basel$152.0M Series B
Onward
April 2026

Onward develops an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools.

Biotechnology · Eindhoven$47.8M Post-IPO Equity
AviadoBio
March 2026

AviadoBio transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies

Biotechnology · LondonGrant
Egle Therapeutics
March 2026

Egle Therapeutics is a biotechnology company focused on developing immunotherapies for oncology and autoimmune diseases.

Biotechnology · Paris$9.4M Grant
Exciva
January 2026

Exciva develops clinical-stage biopharmaceutical therapies focused on addressing neuropsychiatric symptoms associated with dementia.

Biotechnology · Heidelberg$59.4M Series B
Kinaset Therapeutics
January 2026

Kinaset Therapeutics is a biopharma company that focuses on advancement of novel drugs in areas of unmet medical needs.

Health Care · Boston$103.0M Series B
ViCentra
January 2026

ViCentra has developed an insulin pump for diabetes patients.

Health Care · Utrecht$13.0M Series D
FoRx Therapeutics
December 2025

FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways.

Biotechnology · Basel$50.0M Series A
Artios Pharma
November 2025

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

Biopharma · Cambridge$115.0M Series D
Tubulis
October 2025

Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications.

Biotechnology · Munich$400.6M Series C
Cyted
August 2025

Cyted uses artificial intelligence (AI) and digital pathology to improve the detection and diagnosis of diseases, including cancer.

Artificial Intelligence (AI) · Cambridge$44.0M Series B
SNIPR Biome
August 2025

SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases.

Biometrics · Copenhagen$40.8M Series B
Neuros Medical
July 2025

Neuros Medical develops neurostimulation therapies for patients suffering with unmet medical needs.

Health Care · Willoughby$56.0M Series D
Splice Bio
June 2025

Splice Bio develops gene therapies using its Protein Splicing platform for genetic diseases.

Biotechnology · Barcelona$135.0M Series B
Mosanna Therapeutics
June 2025

Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea.

Biotechnology · Redwood City$80.0M Series A
Avidicure
April 2025

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.

Oegstgeest$50.0M Seed
Perfuze
March 2025

Perfuze is a medical device company developing catheter-based aspiration technology to treat acute ischemic stroke.

Health Care · Newcastle$23.9M Venture - Series Unknown
VarmX
February 2025

VarmX B.V. is manufacturing therapeutic proteins to instantaneously restore blood clotting in bleeding patients.

Manufacturing · Leiden$15.8M Venture - Series Unknown
Atalanta Therapeutics
January 2025

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

Biotechnology · Boston$97.0M Series B
XyloCor Therapeutics
January 2025

XyloCor Therapeutics is a biopharmaceutical company intended to develop gene therapy for people with coronary artery disease.

Biotechnology · King Of Prussia$67.5M Series B
Noema Pharma
December 2024

Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.

Biotechnology · Basel$147.2M Series B
NUA Surgical
December 2024

NUA Surgical develops a specialised surgical retractor to make C-Sections a safer and superior surgery.

Cosmetic Surgery · Galway$6.9M Series A

Where EQT Life Sciences invests

Biotechnology16
Health Care15
Medical10
Pharmaceutical8
Medical Device8
Therapeutics8

About EQT Life Sciences's portfolio

How many companies has EQT Life Sciences invested in?▸

EQT Life Sciences has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does EQT Life Sciences invest in?▸

EQT Life Sciences's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Medical Device. The firm invests across 15 different industry categories.

What is EQT Life Sciences's largest investment?▸

Among tracked funding rounds, Tubulis received $400.6M in a Series C round. EQT Life Sciences's total known invested capital is $5.2B.

What is the average investment size for EQT Life Sciences?▸

EQT Life Sciences's average investment size is $64.6M across its portfolio of 81 companies.

What are EQT Life Sciences's most recent investments?▸

Recent EQT Life Sciences portfolio additions include AstronauTx, Neurent Medical, Vaderis Therapeutics, Onward, AviadoBio. These companies were founded in 2020 or later.

Reach the founders behind these 81 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →